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Summary
Introduction.— The prognostic signiﬁcance of monitoring risk factors and adjusting treatments
in patients after an acute coronary syndrome (ACS) is well documented. However, studies
over the last few years show that secondary prevention objectives are rarely met. PreventionSecondary
prevention;
Therapeutic
education;
programmes are effective but their beneﬁt is only partially maintained in long-term follow-up.
Aim of the study.— To evaluate the efﬁcacy of a global management programme for atheroscle-
rosis (the CEPTA programme) on the long-term monitoring of cardiovascular risk factors, on
adherence to treatment, and to compare the data of clinical events post-ACS with that con-
tained in the scientiﬁc literature.
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Compliance;
Risk factors
Patients and methods.— Six hundred and sixty consecutive patients were hospitalised three
months after the occurrence of an ACS to evaluate residual risk factors, the atherosclerosis
burden, and to undergo a treatment adjustment and a therapeutic and dietary education
programme. We evaluated the impact of this long-term programme on the balance of risk
factors, treatment maintenance and clinical events. At the end of an average follow-up of 20
months, 96.3% of patients were on antiaggregates, 86.0% were on -blockers or Verapamil®,
62.4% were on angiotensin-converting enzyme inhibitors or angiotensin to receptor antagonists,
88.4% were on cholesterol-lowering medication and 75.5% were receiving a combination of
-blocker antiaggregates and cholesterol-lowering drugs. Monitoring of LDL cholesterol and
blood pressure was done in over 81 and 71% of patients, respectively. At 20 months of
follow-up, total mortality was 3.6% and one cardiovascular event occurred in 12% of patients.
In conclusion, this short programme following ACS is beneﬁcial for the long-term management
of cardiovascular risk factors and the sustainability of drug treatments.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé
Introduction.— L’importance pronostique du contrôle des facteurs de risque et de l’adaptation
thérapeutique chez les patients après un syndrome coronarien aigu (SCA) est bien établie. Pour-
tant, les études montrent que les objectifs de prévention secondaire sont rarement atteints.
Les programmes de prévention sont efﬁcaces mais leur bénéﬁce n’est que partiellement
maintenu dans le suivi à long terme.
But de l’étude.— Évaluer l’efﬁcacité d’un programme de prise en charge globale de
l’athérosclérose (programme Cepta) sur le contrôle à long terme des facteurs de risques
cardiovasculaires, sur l’adhésion au traitement et comparer les données sur les événements
cliniques après un SCA à celles de la littérature.
Patients et méthodes.— Six cent soixante patients consécutifs ont été hospitalisés, trois mois
après la survenue d’un SCA, pour évaluation des facteurs de risques résiduels, de la charge
en athérome ainsi que pour bénéﬁcier d’une adaptation thérapeutique et d’un programme
d’éducation thérapeutique et diététique. Nous avons évalué l’impact de ce programme à long
terme sur l’équilibre des facteurs de risque, le maintien du traitement et les événements
cliniques. Au terme d’un suivi médian de 20 mois, 96,3 % des patients étaient sous antiagré-
gant, 86,0 % étaient sous bêtabloqueur ou Verapamil, 62,4 % sous inhibiteur de l’enzyme de
conversion ou antagoniste des récepteurs à l’angiotensine II, 88,4 % étaient sous un médicament
hypocholestérolémiant et 75,5 % bénéﬁciaient d’une combinaison antiagrégant bêtabloqueur et
hypocholestérolémiant. Le contrôle du LDL cholestérol et de la tension artérielle était obtenu
chez plus de 81 et 71 % des patients respectivement. À 20mois de suivi, la mortalité totale était
de 3,6 % et un événement cardiovasculaire est intervenu chez 12% des patients. En conclusion,
ce programme court à distance du SCA est bénéﬁque sur la prise en charge à long terme des
facteurs de risques cardiovasculaires et sur la pérennité du traitement médicamenteux.
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he majority of intervention studies have established the
rognostic signiﬁcance of long-term monitoring of risk fac-
ors in patients having presented with an acute coronary syn-
rome (ACS) [1,2]. And yet national and international stud-
es show that these guidelines are only partially applied in
aily clinical practice [3—5]. Among these are the Euroaspire
I and III studies, which show the persistently high preva-
ence of changeable risk factors and lifestyles unsuitable for
atients with a proven coronary disease [5,6]. These studies
ighlight the insufﬁcient use of drugs recommended in the
econdary prevention of coronary heart disease. They also
mphasise the efforts required to meet the standards of pre-
entive cardiology by improving lifestyle changes, the mon-
toring of risk factors and the optimal use of prophylactic
rugs so as to reduce cardiovascular morbidity and mortality.
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In response to the difﬁculties of optimising sec-
ndary prevention, optimised management programmes of
therosclerosis have been developed, which rely on the
ational and European guidelines on cardiovascular dis-
ase prevention [7,8]. While considering the efﬁcacy or
ailure of some previously reported prevention actions,
he Centre d’exploration, de prévention et de traitement
e l’athérosclérose (CEPTA) was created at the CHU de
ordeaux for post-ACS patients, the aim of which is to sig-
iﬁcantly improve secondary prevention measures in the
ong-term. This programme includes the initiation of these
easures during hospitalisation for an ACS, and a 48 h stay
uring the third month after the ACS. The programme
s focused on the overall management of the coronary
atient through complete evaluation of the extension of
heir atheroma, myocardial function and risk factors, com-
ined with a therapeutic and dietary education. At the end
••
•
•
•
•
•Short management programme for atherosclerosis
of the 3-month review, particular attention is paid to adjust-
ing the drug prescription according to the guidelines and
the patient’s risk proﬁle. Our hypothesis is that these dif-
ferent management stages of the coronary patient could be
an effective means of improving the secondary prevention
measures.
The main objective of this prospective study is to analyse
the effects of the secondary prevention objectives at the
end of the follow-up. The secondary objective is to report
the morbidity and mortality of this cohort of patients so as
to compare them with the data from the literature.
In this study we report the results demonstrating the
impact of this overall programme post-ACS over time, on the
monitoring of risk factors, the persistence and adherence to
treatment, and the clinical events.
Patients and methods
Study population
We studied a monocentric cohort of patients recruited
consecutively during hospitalisation for ACS. The inclusion
criteria (nine) was the onset of an ACS according to the crite-
ria of the ESC [9]. The diagnosis was established if two serum
values of troponin T appeared to be over 0.05 g/L or if the
CPK-MB were over 10g/L with the typical symptoms (chest
pain lasting more than 15min, pulmonary edema without
signiﬁcant valvulopathy, cardiogenic shock and ventricular
arrhythmia), all with new Q-waves in at least 2 of the stan-
dard 12 electrocardiography leads or electrocardiography
changes indicating acute ischaemia (ST-segment elevation,
ST-segment depression or T-wave inversion). There were no
exclusion criteria.
Acute phase of ACS
Each patient underwent a coronary angiography at the USIC
and received medical treatment during the acute phase
that was the most adapted in relation to the most recent
guidelines. The ACS characteristics included initial electro-
cardiographic modiﬁcations, the affected coronary artery,
increased enzyme levels, initial treatment (angioplasty with
or without stenting and coronary artery bypasses) and acute
complications.
Between two and four days after ACS, the patients were
transferred to CEPTA where they received advice necessary
for their change in lifestyle, diet and not smoking. An opti-
mal treatment was prescribed in the discharge prescription
depending on the cardiovascular condition and risk factors
according to guidelines [7,8].
Intervention at 3months
Three months after the ACS, the patients were sys-
tematically invited for an appointment to assess their
atheromatous disease and its consequences, and to partic-
ipate in the secondary prevention programme described as
follows:
• screening for risk factors: each patient underwent an
assessment of their tobacco consumption, dietary habits
and physical activity. Weight and height were recorded to53
calculate the body mass index (BMI). Blood pressure was
monitored for an hour while lying down and an average
of at least ﬁve measurements was used for data anal-
ysis. Fasting blood samples were taken to measure the
concentration of total cholesterol, LDL and HDL choles-
terol, triglycerides, blood glucose, glycated haemoglobin
and ﬁbrinogen;
personalised dietary advice aiming the nutritional bal-
ance was given to them by the ward’s dietician. Before
this consultation, patients had already answered a ques-
tionnaire concerning their nutritional habits (a one page
per week diary). The aim of this intervention was to cor-
rect the major nutritional mistakes and to set the daily
fat intake to less than 30% of the energy ration and
the saturated fatty acid intake to less than 10% of this
ration. Consumption of cereals, ﬁbres and fruits was rec-
ommended;
active smoking patients underwent a consultation with a
smoking cessation specialist;
an educational session focusing on cardiovascular risk fac-
tors and on lifestyle habits was conducted by the nurses
and cardiologists of the ward and the nutritional session
was conducted by the dieticians. Comprehensive educa-
tion was given on all aspects of coronary disease, including
changes in lifestyle habits, blood pressure, smoking, and
management of diabetes and cholesterol;
discharge medication was scrupulously adapted to the
cardiac condition, risk factors and speciﬁc objectives to
be met in accordance with guidelines. This treatment
included -blockers (if contraindication, Verapamil® was
prescribed), ACE inhibitors or AT2 receptor agonist, and
patients who still had high blood pressure could receive
one or several additional antihypertensive drugs. Anti-
aggregates (aspirin and clopidogrel) and hypolipidaemic
medication (statins or ﬁbrates) were also used in combina-
tion. Diabetic patients received oral antidiabetic agents
and/or an insulin treatment after discussion with the dia-
betes specialist;
assessment of the left ventricle ejection fraction via
echocardiography and isotopic ventriculography and
screening for residual myocardial ischaemia via 99mTc-MIBI
myocardial perfusion scintigraphy;
assessment of the atherosclerosis burden:
◦ coronary atheroma: coronary stenoses were quantiﬁed
on digital angiography measurements of the coro-
nary angiographies performed during the acute phase.
Stenoses estimated as at least 50% were retained as
signiﬁcant so as to quantify the single-, two- or three-
vessel disease of the patient,
◦ carotid atheroma: carotid stenoses were quantiﬁed
during a cervical ultrasonography examination. The
stenoses were expressed in reduction percentage of
diameter according to the NASCET criteria. The cri-
terion retained for this study was the presence of a
stenosis of at least 20%;
arteriopathy of the lower limbs: the arteriography diagno-
sis was established with an abnormal measurement (< 0.9
or > 1.4) of the Ankle Brachial Index (ABI). Thus, systolic
pressure measurements were recorded from the posterior
tibial arteries, the dorsalis pedis arteries, and the two
brachial arteries on a patient lying in the dorsal decubi-
tus position at rest for at least 5min by using a handheld
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statistics were reported as numbers and percentages. The4
continuous wave Doppler unit at 8MHz and an adjustable
cuff. For each ankle, the ABI measurement was obtained
by calculating the ratio between the highest pressure of
each ankle and the highest brachial artery pressure. The
lowest ABI on the right or the left was retained for the
continuation of the analysis, corresponding to the global
ABI of the patient [10].
ollow-up
atients were monitored by their usual doctor or their
ardiologist and were not contacted by the CEPTA until
nal follow-up. Follow-up was obtained via a standard-
sed questionnaire sent to each patient and each doctor
pproximately 18 months after the patient’s last visit.
his easy-to-understand questionnaire enabled us to gauge
ymptoms, the onset of an event (recurrence of infarction,
troke, arteriopathy of lower limbs or an angioplasty-type
ntervention, bypass and endarterectomy), lifestyle habits
smoking and physical activity), weight and ongoing treat-
ent. The usual doctor measured blood pressure. A blood
ample was taken (identiﬁcation of lipid abnormality, blood
lucose and glycated haemoglobin) to evaluate the risk fac-
ors. When events occurred during follow-up, we resorted
o the hospitalisation reports. The events were classiﬁed as
ajor (cardiovascular death, ACS, stroke) and minor (heart
ailure, coronary or peripheral revascularisation).ssessment criteria and deﬁnitions
atients included in the study were those who completed
he 3-month analysis. Data concerning deceased or non-
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Table 1 Characteristics of the acute coronary syndrome (ACS
tion. The ejection fraction was measured at 3months using the
Age (years)
Women (%)
History of cardiovascular disease (%)
ACS with ST-segment elevation (%)
ACS localisation
Anterior (%)
Inferior (%)
Lateral (%)
ACS treatment
Fibrinolysis±primary angioplasty (%)
Conventional treatment (%)
Coronary bypasses (%)
Early cardiac insufﬁciency or recurrent ACS (%)
Isotopic ejection fraction (%)
Ejection fraction < 45% (%)
Extension of atheroma
One coronary artery affected (%)
Two coronary arteries affected (%)
Three coronary arteries affected (%)
Cervical atherosclerosis (%)
ABI < 0.9 (%)
ABI > 1.4 (%)M. Laﬁtte et al.
ospitalised patients between the time of the ACS and
ospitalisation at 3months were reported. All patients seen
t 3months were monitored for 2 years.
The primary objective of this prospective study is to eval-
ate the effect of this prospective programme on meeting
he secondary prevention objectives at 2 years after ACS.
he secondary objective is to evaluate the morbidity and
ortality in this group. In the absence of a control group,
comparison with data in the literature will be done. How-
ver the primary objective enables us to conclude on the
mpact of this effect, insofar as these objectives are deﬁned
y the scientiﬁc community. The set objectives are deﬁned
ccording to the following criteria: LDL cholesterol below
.35mmol/L (current criteria during the patient inclusion
eriod), HDL cholesterol above 1.03mmol/L, triglycerides
elow 1.69mmol/L, blood pressure below 140/90mmHg,
bA1c below 7%, waistline below 102 cm for men and 98 cm
or women.
eﬁnitions for statistical analysis
he initial protocol was validated by the team of methodol-
gists at the CHU.
The data were analysed through descriptive and ana-
ytical statistics. The category variables, the descriptiveifference in distribution of certain category variables was
xamined by using a Chi-square test. A paired t-test was
sed to compare continuous variables. Analyses were per-
ormed using the Statview 5.0.1 software and verifying using
TATA. A value of p < 0.05 was considered signiﬁcant.
) and the extension of atherosclerosis in the total popula-
isotopic method.
Total population N = 660
59.7 ± 12.8
18.1
16
65.4
43.9
39.1
17.0
75.2
18.6
6.2
4.8
55.3 ± 12
18.0
49.2
28.8
14.7
31.9
17.1
5.4
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Table 2 The medical treatments after patient discharge at 3months and at time of follow-up.
Percentage of patients treated with 3months (N = 660) Follow-up (N = 638)
-blocker or a calcium antagonist 97.9 86.0
Cholesterol-lowering medication 94.3 88.4
Antiaggregate 100 96.3
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-blocker + antiaggregate + cholesterol-lowering medicatio
Results
Initial characteristics of the ACS and extension
of the atheroma
From January 2001 to July 2004, 685 consecutive men and
women were hospitalised for a coronary syndrome. Six hun-
dred and sixty patients were hospitalised again at 3months,
while 20 patients refused hospitalisation and ﬁve patients
deceased over the same period. The cardiac and vascular
demographic data and the characteristics of the treatment
for these patients are shown in Table 1.
Over 40% of patients had a signiﬁcant coronary stenosis
in two or three vessels and one third of patients had carotid
atheromatous plaques, while over 20% presented with an
arterial disease of the lower limbs diagnosed through an
ABI below 0.9 or above 1.4 with or without intermittent
claudication.
Following hospital discharge after the coronary syn-
drome, 97.9% of patients received a -blocker or a calcium
antagonist, 94.3% took cholesterol-lowering medication,
100% were treated with an antiaggregate, 82% received an
angiotensin converting enzyme inhibitor or an angiotensin II
receptor antagonist (Table 2).
Cardiovascular risk factors at 3months and
follow-up
The average follow-up time was 621 days (interquartile
492—730) from the initial episode of the ACS. Two patients
were lost to follow-up (0.4%). The rate of available informa-
tion concerning lifestyle, risk factors, laboratory parameters
and treatments collected at the time of follow-up was over
95%.
The medicinal treatments at the time of follow-up
were the following: 96.3% of patients were on antiag-
gregates, 86.0% were on -blockers or Verapamil®, 62.4%
were on ACE inhibitors or AT2 receptor agonist, and
88.4% were on cholesterol-lowering medication. Moreover,
75.5% of patients took an antiaggregate, a -blocker or
Verapamil® and a cholesterol-lowering medication simulta-
neously (Table 2). Besides, 3.7% of patients did not take an
antiaggregate, of which half were due to gastric intolerance
or the need for an oral anticoagulant treatment and the
other half for no known reason.
The prevalence and distribution of risk factors at
3months and at follow-up are included in Table 3. Therapeu-
tic control of LDL cholesterol levels was achieved in 81.5%
of patients (with a recommended LDL target level below
3.35mmol/L at the time of the study). Among the patients
with an LDL cholesterol level above 3.35mmol/L, 30% had
c
s
t
t
ctor agonist 82 62.4
91.2 75.5
topped their statin medication, of which half were due to
uscular or hepatic intolerances. A third of them were on a
ow-strength statin.
Therapeutic control of blood pressures was achieved in
1.1% of patients. In patients with ongoing hypertension,
nly 16% had a systolic pressure above 160mmHg. The 3-
onth evaluation of the whole population revealed that
.7% presented electrical left ventricular hypertrophy and
3.6% presented echocardiographic left ventricular hyper-
rophy.
The glycaemic parameters were correctly controlled with
table values in the follow-up period.
Tobacco control was improved with the intervention of a
moking cessation specialist in resistant smokers who had
ot quit during the ﬁrst 3months after ACS. After inter-
ention by the specialist, 18% of smokers quit during the
ollow-up. Surprisingly, some former smokers (patients who
o longer smoked at the time of ACS) resumed their tobacco
se during the follow-up. In total, 18.6% of patients smoked
t follow-up after the ACS compared with 16.8% at 3months.
We noticed a signiﬁcant decrease in the triglyceride
evels, stable BMI and improvement in physical activity
Table 4).
linical events
uring the 20months of follow-up after hospital discharge
or ACS, the total mortality rate was 4.3%. During the
7months of follow-up after the intervention at 3months,
.6% of patients were deceased: 2.4% died of cardiovascular
iseases (fatal myocardial infarction and sudden death) and
.2% from cancer (seven patients) or pulmonary embolism
one patient). We recorded a total of 12% cardiovascular
vents including 6.5% major events (cardiovascular death,
CS or cerebrovascular accident). Details of the clinical
vents are listed in Table 4.
We demonstrate that there is no signiﬁcant difference in
he rates of cardiovascular events at 20 months in the less
han 65 years and more than 65 years groups.
iscussion
he programme proposed by the CEPTA focuses on optimis-
ng secondary prevention management by combining coro-
ary patient information and education, clinical and para-
linical evaluations of their ischaemic cardiomyopathy and
ardiovascular risk, and drug and dietary interventions. This
tudy demonstrates the need for the long-term evaluation of
he acute episode due to the persistent number of risk fac-
ors at 3months. It also demonstrates the feasibility and efﬁ-
acy of this short programme, staggered in time compared
56 M. Laﬁtte et al.
Table 3 Evolution of cardiovascular risk factors between the third month after the ACS and follow-up.
3months (N = 660) Follow-up (N = 638) p
Dyslipidaemia
Total cholesterol (mmol/L) 5.07± 1.0 4.69± 0.9 < 0.0001
LDL cholesterol (mmol/L) 3.00± 0.8 2.72± 0.7 < 0.0001
% of patients with LDL > 3.35mmol/L 33.1 18.5 < 0.00001
HDL cholesterol (mmol/L) 1.30± 0.3 1.27± 0.3 < 0.02
% of patients with HDL <1.03mmol/L 19.8 25.5 < 0.05
Triglycerides (mmol/L) 1.74± 1.2 1.55± 1.2 < 0.002
% of patients with TG> 1.69mmol/L 38.3 28.4 < 0.001
Hypertension
Systolic blood pressure (mmHg) 119.8± 17 129.5± 11 < 0.0001
Diastolic blood pressure (mmHg) 65.9± 11 75.0± 8 < 0.0001
% of patients with SBP≥ 140mmHg or DBP≥ 90 13.0 28.9 < 0.0001
Diabetes
Fasting blood glucose (mmol/L) 6.14± 2.0 5.94± 1.9 0.33
Haemoglobin A1c (%) 6.0± 1.0 5.9± 1.0 0.72
% of patients with diabetes 24.2 —
Fasting blood glucose (mmol/L) in diabetic patients 8.59± 2.9 8.17± 3.0 0.29
Haemoglobin A1c (%) in diabetic patients 7.12± 1.4 7.17± 1.3 0.43
% of patients with HbA1c≥ 7% in diabetic patients 37.9 47.5 0.16
Creatinine clearance (ml/min) 84.3± 28.7
Body mass index (kg/m2) 27.4± 4.7 27.6± 4.6 < 0.02
% of patients with a BMI > 30 23.9 24.9 0.81
Waist circumference (cm) 98.8± 12.4 — —
Active smoker (%) 16.8 18.6 0.45
Family history of cardiovascular disease (%) 28.6 — —
Physical activity
None (%) 60.1 39.4
Moderate (%) 33.6 47.3 < 0.01
Intense (%) 6.3 13.3
Socioeconomic status
Low (%) 15.6 — —
Average (%) 73.7 — —
High (%) 10.6 — —
% of patients presenting with risk factors
0 risk factor 28.1 42.5 0.00001
1 risk factor 33.0 34.2
2 risk factors 25.6 15.1
3 risk factors 9.5 5.7
4 risk factors 2.8 1.9
5 risk factors
Table 4 Cardiovascular events during follow-up in total popu
65 years.
Total population Pa
Death 3.6% (24) 4.8
Cardiovascular death 2.4% (16) 2.8
Death other causes 1.2% (8) 2%
Major cardiovascular events 6.5% (43) 7.6
Cardiovascular death 2.4% (16) 2.8
Acute coronary syndromes 3.4% (23) 4%
Cerebrovascular accidents 0.7% (4) 0.8
Minor cardiovascular events 5.5% (37) 6.8
Revascularisation 3.9% (26) 3.2
Cardiac insufﬁciency 1.6% (11) 3,60.9 0.4
lation in the groups of patients above 65 years and below
tients > 65 years (37.8%) Patients < 65 years (62.2%)
% (12) 2.9% (12)
% (7) 2.1% (9)
(5) 0.8 %(3)
% (19) 5.8% (24)
% (7) 2.2% (9)
(10) 3.1% (13)
% (2) 0.5% (2)
% (17) 4.8% (20)
% (8) 4.3% (18)
% (9) 0.5% (2)
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with the acute event, and the overall impact of management
of atherosclerosis in patients after an ACS on their treatment
compliance and reduction of their cardiovascular risk.
Previous studies have reported the impact of programmes
intended to improve risk factors in coronary patients or
to improve their level of treatment, speciﬁcally in lipid-
lowering specialised centres or in cardiac rehabilitation
programmes [11—16]. We were inspired by this already val-
idated type of system to develop a more global approach
to atherosclerotic disease. We noticed how long-term con-
trol of risk factors failed in several studies, especially in
patients after cardiac rehabilitation. It is whilst consider-
ing this time restriction that we developed a programme
at 3months after the onset of ACS, a time when patient
motivation decreases and when risk factors reappear. On the
other hand, this visit after 3months enables a reliable eval-
uation of the persistent or recurrent myocardial ischaemia,
the myocardial function, and the risk factors at the same
time. The main points of the programme that we developed
are summarised as followed:
• the programme is conducted by cardiologists because it
has been shown that they more readily use recommended
therapeutic strategies to improve the coronary condition
of patients [15,17];
• the group made up of cardiologists, specialist nurses and
a psychologist developed a tailor-made programme to
manage the coronary disease of each patient (with a
combination of patient information on the main practical
rules, patient education, appropriate consultations and
adapted quality care offered [18—20]. This type of inter-
vention proved to be effective in improving coronary risk
factors, reducing hospital admissions and improving the
quality of life or functional abilities of coronary patients;
• the programme included implementing secondary pre-
vention measures immediately after ACS before hospital
discharge. This early start proved to be effective in
improving therapeutic dosage, long-term compliance of
the patient and clinical events [12,21];
• special attention was made to adjusting the medica-
tion dose in relation to the risk level. Most coronary
patients have not reached the recommended LDL choles-
terol target levels, speciﬁcally due to underdosage of the
cholesterol-lowering medication [5]. Insufﬁcient medica-
tion was identiﬁed as a predictive factor independent of
the coronary event after the ACS [22]. This insufﬁcient
medication adjustment may be extended to other risk
factors, speciﬁcally hypertension and or diabetes [23,24];
• the uniqueness of our programme lies in a hospital stay
lasting 48 h, 3months after ACS. It has been shown that
the beneﬁt of cardiac rehabilitation following ACS is only
partially maintained during the ﬁrst year [25,26]. For
example, among the patients who were prescribed the
key medications following their discharge from rehabilita-
tion, 8 to 20% no longer took this drug after 6months [27].
The reasons for this poor long-term compliance are com-
plex, but we have shown that a staggered programme is a
better strategy to target the compliance problem and to
improve the long-term outcome of the coronary patient.
A multifactorial approach requires a structured and
intensive strategy that goes beyond the simple treatment
of blood cholesterol or hypertension, by addressing the
A
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xtension of the atheroma and its consequences, and all
ardiovascular risk factors. This programme does not use
ny new medications or a behaviour modiﬁcation model,
ut includes an introduction and tailor-made adjustment
f medications in relation to the established targets, and
xplanations on the relevance of each medication taken by
he patient [27]. In this study, we observed a positive impact
n the adherence to treatment 20 months after ACS with
latelet antiaggregates, -blockers or statin. This adher-
nce is well above the one observed in the French cohort
f Euroaspire II, in which the average follow-up period was
uch shorter [5]. The rate of treatment discontinuation in
he GRACE Registry was 8% for aspirin, 12% for -blockers
nd 13% for statins at 6months, namely a higher discontin-
ation rate than our cohort for a shorter follow-up period
27].
This is reﬂected in a reduction of long-term risk factors
ith better efﬁcacy on the secondary prevention objectives.
n the absence of a control group, this study does not enable
s to evaluate the impact of this programme on cardiovascu-
ar events, but the rate of cardiovascular events or of death
s decreased by half compared with the results recently pub-
ished on this type of patient cohort. In the GRACE registry,
he death rate at 6months in ACS survivors is 4.8% in patients
resenting myocardial infarction with ST-segment elevation
nd 6.2% in patients presenting with ACS without ST-segment
levation [6]. Mortality in our study is decreased by nearly
alf and yet our follow-up is three times longer. Moreover,
he mortality rate of patients is more than half lower than
hat reported in the USIC 2000 study, which studied the
ortality at 1 year after myocardial infarction [28,29].
A signiﬁcant limitation of our study is the lack of a con-
rol group. We had planned to study the patient group
hich would not have agreed to undergo the programme
months after their ACS but only 20 patients refused
his programme. On the other hand, management during
he acute phase and especially the high rate of direct
ngioplasties may have a positive impact on long-term
vents.
The characteristics of this population are comparable
o those reported in the ACS series, with a great pro-
ortion of men presenting with an ACS and ST-segment
levation and a high percentage with anterior infarction.
he 5% rate of heart failure or recurrence of ACS dur-
ng the acute phase is comparable with the published
ata and demonstrates the severe myocardial condition
f our patients. The prevalence of diabetes or periph-
ral arterial disease is also comparable with the reported
eries.
Regardless, this study demonstrates the beneﬁt of a
lobal and staggered management of atherosclerosis in 660
onsecutive patients 3months after ACS on the long-term
ontrol of risk factors and adherence to treatment, which
re determining elements in reducing the cardiovascular
orbidity and mortality after ACS.cknowledgment
e are indebted to the members of the CEPTA team: dieti-
ians, nurses and psychotherapist.
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